Trials / Conditions / Stage IIIA Melanoma

Stage IIIA Melanoma

15 registered clinical trials studyying Stage IIIA Melanoma.

Status	Trial	Sponsor	Phase
Completed	APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255	Wake Forest University Health Sciences	Phase 1
Terminated	High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By NCT02203604	CINJRegulatory	Phase 2
Completed	Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic NCT02094872	Yale University	Phase 2
Terminated	Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or NCT01835184	National Cancer Institute (NCI)	Phase 1
Terminated	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Region NCT01701037	Vanderbilt-Ingram Cancer Center	Phase 2
Completed	Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery NCT01748747	Mayo Clinic	EARLY_Phase 1
Terminated	FDG-PET in Advanced Melanoma NCT02236546	Vanderbilt-Ingram Cancer Center	N/A
Terminated	Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior NCT01519427	National Cancer Institute (NCI)	Phase 2
Terminated	Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery NCT01533948	Roswell Park Cancer Institute	Phase 2
Completed	Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma NCT01321437	University of California, Irvine	Phase 2
Completed	Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00470470	National Cancer Institute (NCI)	Phase 2
Completed	Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma NCT00436605	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma NCT00089063	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma NCT00085189	University of Southern California	Phase 2
Completed	Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma NCT00003895	National Cancer Institute (NCI)	Phase 2